MedTrace Logo

Assessment of PCSO-524 Relative to a Comparator Product

NCT01564160 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-12-03

No results posted yet for this study

Summary

A marine lipid oil extract isolated from the New Zealand Greenshell® Mussel, Perna canaliculus (P. canaliculus), contains a unique synergistic blend of marine fatty acids.

The objective of the this study is to evaluate the acute (5-hour) and chronic (21-day) bioavailability of a fixed dose of PCSO-524 compared to a fish oil product in a population of healthy adult participants.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Fish Oil

Source of omega-3 fatty acids.

DIETARY_SUPPLEMENT

PCSO-524

Extract of Greenshell Mussel

Sponsors & Collaborators

  • Pharmalink International Ltd.

    collaborator UNKNOWN

  • Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

    lead NETWORK

Principal Investigators

  • Maggie D Laidlaw, Ph.D · Nutrasource Diagnostics

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01564160 on ClinicalTrials.gov